Otsuka Pharmaceuticals Europe Files MAA with EMA for Voclosporin

Article

Otsuka Pharmaceuticals Europe has filed an initial marketing authorization application to the European Medicines Agency for voclosporin.

Otsuka Pharmaceuticals Europe, a subsidiary of Otsuka Pharmaceuticals Co., Ltd., has filed an initial marketing authorization application (MAA) to the European Medicines Agency (EMA) for voclosporin—an investigational, oral calcineurin inhibitor.

According to a June 25, 2021 press release, the European MAA has been submitted for voclosporin to be used as a treatment of lupus nephritis (LN), a complication of the autoimmune disease systemic lupus erythematosus (SLE). The drug is administered orally and works by inhibiting calcineurin, an enzyme that is important for the proliferation and activation of T-cells.

In December 2020, Aurinia Pharmaceuticals and Otsuka Pharmaceuticals entered a collaboration and license agreement for the development and commercialization of oral voclosporin as a treatment for LN in the European Union, Japan, United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein, and Ukraine. FDA has also approved, in January 2021, voclosporin in combination with a background immunosuppressive therapy regimen for the treatment of adults with active LN.

Source: Otsuka Pharmaceuticals

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes